Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | CCNC | P24863 | 3/20 | 0.43 |
| ▸ | CDK8 | P49336 | 3/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6376840 | 1.00 | CA12 (0.45) | CA12CA1CA2CA7CA9 | |
| SCHEMBL15765005 | 0.84 | CA12 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2490683 | 0.83 | CA12 (0.41) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2490681 | 0.83 | CA12 (0.41) | CA12CA1CA2CA7CA9 | |
| SCHEMBL23723019 | 0.81 | CA12 (0.42) | CA12CA1CA2CA7CA9 | |
| SCHEMBL18106169 | 0.81 | FDPS (0.41) | CA12CA1CA2CA7CA9 | |
| SCHEMBL18164607 | 0.80 | IAPP (0.38) | NPC1RAB9AMAPTHTTFDPS | |
| SCHEMBL15765070 | 0.78 | RAB9A (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7171507 | 0.77 | PTP4A3 (0.38) | RAB9AMAPTLMNAHTTFDPS | |
| SCHEMBL1756847 | 0.77 | TBXAS1 (0.40) | CCNCCDK8LMNACYP3A4FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11420944-B2 | Voltage-dependent t-type calcium channel blocker | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-08-23 | — | — | US | disclosed |
| US-20190077767-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL BLOCKER | NIPPON CHEMIPHAR CO., LTD. (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3404021-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL INHIBITOR | Nippon Chemiphar Co., Ltd. (JP) | 2018-11-21 | — | — | EP | disclosed |
| US-20050153964-A1 | Pyrimidone compounds which are inhibitors of the enzyme Lp-PLA2; use in treating atheroscelerosis | GLAXO GROUP LIMITED (GB) | 2005-07-14 | — | — | US | disclosed |
| EP-1492787-A2 | (CONDENSED) PYRIMIDONE AND (CONDENSED) PYRIDONE COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003087088-A2 | (CONDENSED) PYRIMIDONE AND (CONDENSED) PYRIDONE COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153964-A1 | Pyrimidone compounds which are inhibitors of the enzyme Lp-PLA2; use in treating atheroscelerosis | LYPLAL1, PLA2G12A, ENPP2 | CA12 4705/4885CA1 4680/4885CA2 4032/4885 |
| US-11420944-B2 | Voltage-dependent t-type calcium channel blocker | CACNA1I, CACNA1G, CACNA1E | CA12 2236/4885CA1 868/4885CA2 99/4885 |
| US-20190077767-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL BLOCKER | CACNA1I, CACNA1G, CACNA1E | CA12 1971/4885CA1 592/4885CA2 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.